1.Freedman, MS, Selchen, D, Arnold, DL, et al.Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci. 2013;40:307–323.
2.Thompson, AJ, Banwell, BL, Barkhof, F, et al.Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162–173.
3.Lublin, FD.New multiple sclerosis phenotypic classification. Eur Neurol. 2014;72 Suppl 1:1–5.
4.Kappos, L, Freedman, MS, Polman, CH, et al.Effect of early versus delayed interferon beta-1b treatment on disability after a ﬁrst clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370:389–397.
5.Freedman, MS, Comi, G, De Stefano, N, et al.Moving toward earlier treatment of multiple sclerosis: findings from a decade of clinical trials and implications for clinical practice. Mult Scler Relat Disord. 2014;3:147–155.
6.van der Vuurst de Vries, RM, Mescheriakova, JY, Wong, YYM, et al.Application of the 2017 revised McDonald Criteria for multiple sclerosis to patients with a typical clinically isolated syndrome. JAMA Neurol. 2018;75:1392–1398.
7.Calabrese, M, Gasperini, C, Tortorella, C, et al.“Better explanations” in multiple sclerosis diagnostic workup: a 3-year longitudinal study. Neurology. 2019;92:e2527–e2537.
8.Traboulsee, A, Létourneau-Guillon, L, Freedman, MS, et al.Canadian Expert Panel Recommendations for MRI use in MS diagnosis and monitoring. Can J Neurol Sci. 2015;42:159–167.
9.Sati, P, Oh, J, Constable, RT, et al.The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nat Rev Neurol. 2016;12:714–722.
10.Filippi, M, Preziosa, P, Meani, A, et al.Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. Lancet Neurol. 2018;17:133–142.
11.Stangel, M, Fredrikson, S, Meinl, E, Petzold, A, Stüve, O, Tumani, H.The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat Rev Neurol. 2013;9:267–276.
12.Jarius, S, Paul, F, Aktas, O, et al.MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018;15:134.
13.Lebrun-Frenay, C, Kantarci, O, Siva, A, et al. Radiologically isolated syndrome: a 10-year follow-up study to identify factors predicting a clinical event (abstract 97). Presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Stockholm, Sweden, October 11–13, 2019.
14.Okuda, DT, Siva, A, Kantarci, O, et al.Radiologically isolated syndrome: 5-year risk for an initial clinical event. PLoS One. 2014;9:e90509.
15.Makhani, N, Lebrun, C, Siva, A, et al.Oligoclonal bands increase the specificity of MRI criteria to predict multiple sclerosis in children with radiologically isolated syndrome. Mult Scler J Exp Transl Clin. 2019;5:2055217319836664.
16.Suthiphosuwan, S, Sati, P, Guenette, M, et al.The central vein sign in radiologically isolated syndrome. AJNR Am J Neuroradiol. 2019;40:776–783.
17.Tornatore, C, Phillips, JT, Khan, O, Miller, AE, Hughes, M.Consensus opinion of US neurologists on practice patterns in RIS, CIS, and RRMS: evolution of treatment practices. Neurol Clin Pract. 2016;6:329–338.
18.Alshamrani, F, Alnajashi, H, Freedman, M.Radiologically isolated syndrome: watchful waiting vs. active treatment. Expert Rev Neurother. 2017;17:441–447.
19.Jacobs, LD, Beck, RW, Simon, JH, et al.Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000;343:898–904.
20.Comi, G, Filippi, M, Barkhof, F, et al.Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001;357:1576–1582.
21.Kappos, L, Polman, CH, Freedman, MS, et al.Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67:1242–1249.
22.Comi, G, Martinelli, V, Rodegher, M, et al.Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:1503–1511.
23.Comi, G, De Stefano, N, Freedman, MS, et al.Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol. 2012;11:33–41.
24.Miller, AE, Wolinsky, JS, Kappos, L, et al.Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology. 2014;13:977–986.
25.Leist, TP, Comi, G, Cree, BA, et al.Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurology. 2014;13:257–267.
26.Freedman, MS, Leist, TP, Comi, G, et al.The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: results from the ORACLE-MS study. Mult Scler J Exp Transl Clin. 2017;3:2055217317732802.
27.Kinkel, RP, Dontchev, M, Kollman, C, et al.Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. Arch Neurol. 2012;69:183–190.
28.Kappos, L, Edan, G, Freedman, MS, et al.The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology. 2016;87:978–987.
29.Miller, AE, Vermersch, P, Kappos, L, et al.Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: results of the TOPIC extension study. Mult Scler Relat Disord. 2019;33:131–138.
30.The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655–661.
31.Johnson, KP, Brooks, BR, Cohen, JA, et al.Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology. 1995;45:1268–1276.
32.Jacobs, LD, Cookfair, DL, Rudick, RA, et al.Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39:285–294.
33.PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352:1498–1504.
34.O’Connor, P, Wolinsky, JS, Confavreux, C, et al.Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365:1293–1303.
35.Giovannoni, G, Comi, G, Cook, S, et al.A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416–426.
36.Gold, R, Kappos, L, Arnold, DL, et al.Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098–1107.
37.Hauser, SL, Bar-Or, A, Comi, G, et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376:221–234.
38.Chalmer, TA, Baggesen, LM, Nørgaard, M, et al.Early versus later treatment start in multiple sclerosis: a register-based cohort study. Eur J Neurol. 2018;25:1262–e110.
39.Brown, JWL, Coles, A, Horakova, D, et al.Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA. 2019;321:175–187.
40.Iaffaldano, P. The optimal time to start treatment in relapsing remitting multiple sclerosis patients: results from the Big Multiple Sclerosis Data Network (abstract 204). Presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Germany, October 10–12, 2018.
41.Gliklich, R, Dreyer, N, Leavy, M, eds. Registries for evaluating patient outcomes: a user’s guide. Third edition. Agency for Healthcare Research and Quality publication No. 13(14)-EHC111. Rockville, MD, 2014. www.effectivehealthcare.ahrq.gov/registries-guide-3.cfm. Accessed October 1, 2019.
42.Mikol, DD, Barkhof, F, Chang, P, et al.Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7:903–914.
43.Fox, RJ, Miller, DH, Phillips, JT, et al.Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367:1087–1097.
44.Vermersch, P, Czlonkowska, A, Grimaldi, LM, et al.Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler. 2014;20:705–716.
45.Li, H, Hu, F, Zhang, Y, Li, K.Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. J Neurol. 2019;epublished May 25, 2019.
46.Polman, CH, O’Connor, PW, Havrdova, E, et al.A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899–910.
47.Kappos, L, Radue, EW, O’Connor, P, et al.A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387–401.
48.Cohen, JA, Coles, AJ, Arnold, DL, et al.Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380:1819–1828.
49.Damasceno, A, Von Glehn, F, Brandão, CO, Damasceno, BP, Cendes, F.Prognostic indicators for long-term disability in multiple sclerosis patients. J Neurol Sci. 2013;324:29–33.
50.Saeedi, J, Rieckmann, P, Yee, I, Tremlett, H.UBC MS clinic neurologists. Characteristics of multiple sclerosis in aboriginals living in British Columbia, Canada. Mult Scler J. 2012;18:1239–1243.
51.Fisniku, LK, Brex, PA, Altmann, DR, et al.Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 2008;131(Pt 3):808–817.
52.Manouchehrinia, A, Hedström, AK, Alfredsson, L, Olsson, T, Hillert, J, Ramanujam, R.Association of pre-disease body mass index with multiple sclerosis prognosis. Front Neurol. 2018;9:232.
53.Tettey, P, Siejka, D, Simpson, S Jr, et al.Frequency of comorbidities and their association with clinical disability and relapse in multiple sclerosis. Neuroepidemiology. 2016;46:106–113.
54.McKay, KA, Tremlett, H, Fisk, JD, et al.Psychiatric comorbidity is associated with disability progression in multiple sclerosis. Neurology. 2018;90:e1316–e1323.
55.Tomassini, V, Fanelli, F, Prosperini, L, Cerqua, R, Cavalla, P, Pozzilli, C.Predicting the profile of increasing disability in multiple sclerosis. Mult Scler. 2019;25:1306–1315.
56.Spelman, T, Meyniel, C, Rojas, JI, et al.Quantifying risk of early relapse in patients with first demyelinating events: prediction in clinical practice. Mult Scler. 2017;23:1346–1357.
57.Tintore, M, Rovira, À, Río, J, et al.Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain. 2015;138(Pt 7):1863–1874.
58.Kalincik, T, Buzzard, K, Jokubaitis, V, et al.Risk of relapse phenotype recurrence in multiple sclerosis. Mult Scler. 2014;20:1511–1522.
59.Novakova, L, Axelsson, M, Malmeström, C, et al.Searching for neurodegeneration in multiple sclerosis at clinical onset: diagnostic value of biomarkers. PLoS One. 2018;13:e0194828.
60.Rotstein, D, Montalban, X.Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol. 2019;15:287–300.
61.Harris, VK, Sadiq, SA.Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making. Mol Diagn Ther. 2009;13:225–244.
62.Heidari, M, Radcliff, AB, McLellan, GJ, et al.Evoked potentials as a biomarker of remyelination. Proc Natl Acad Sci USA. 2019;epublished December 16, 2019.
63.Chisari, CG, Toro, MD, Cimino, V, et al.Retinal nerve fiber layer thickness and higher relapse frequency may predict poor recovery after optic neuritis in MS patients. J Clin Med. 2019;8. pii: E2022.
64.Kim, NH, Kim, HJ, Park, CY, Jeong, KS.Retinal degeneration after first-ever optic neuritis helps differentiate multiple sclerosis and neuromyelitis optica spectrum disorder. Front Neurol. 2019;10:1076.
65.Zhang, T, Tremlett, H, Leung, S, et al.Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis. Neurology. 2016;86:1287–1295.
66.Kowalec, K, McKay, KA, Patten, SB, et al.Comorbidity increases the risk of relapse in multiple sclerosis: a prospective study. Neurology. 2017;89:2455–2461.
67.Zhang, T, Tremlett, H, Zhu, F, et al.Effects of physical comorbidities on disability progression in multiple sclerosis. Neurology. 2018;90:e419–e427.
68.Scherder, R, Kant, N, Wolf, ET, Pijnenburg, B, Scherder, EJ.Psychiatric and physical comorbidities and pain in patients with multiple sclerosis. J Pain Res. 2018;11:325–334.
69.Conway, DS, Thompson, NR, Cohen, JA.Influence of hypertension, diabetes, hyperlipidemia, and obstructive lung disease on multiple sclerosis disease course. Mult Scler. 2017;23:277–285.
70.Marrie, RA.Comorbidity in multiple sclerosis: implications for patient care. Nat Rev Neurol. 2017;13:375–382.
71.Degelman, ML, Herman, KM.Smoking and multiple sclerosis: a systematic review and meta-analysis using the Bradford Hill criteria for causation. Mult Scler Relat Disord. 2017;17:207–216.
72.Amato, MP, Derfuss, T, Hemmer, B, et al.Environmental modifiable risk factors for multiple sclerosis: report from the 2016 ECTRIMS focused workshop. Mult Scler. 2017;Jan 6:1352458516686847.
73.Esposito, S, Bonavita, S, Sparaco, M, Gallo, A, Tedeschi, G.The role of diet in multiple sclerosis: a review. Nutr Neurosci. 2018;21:377–390.
74.Løken-Amsrud, KI, Holmøy, T, Bakke, SJ, et al.Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment. Neurology. 2012;79:267–273.
75.Fitzgerald, KC, Munger, KL, Köchert, K, et al.Association of vitamin D levels with multiple sclerosis activity and progression in patients receiving interferon beta-1b. JAMA Neurol. 2015;72:1458–1465.
76.Muris, AH, Smolders, J, Rolf, L, et al.Vitamin D status does not affect disability progression of patients with multiple sclerosis over three year follow-up. PLoS One. 2016;11:e0156122.
77.Kampman, MT, Steffensen, LH, Mellgren, SI, Jørgensen, L.Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Mult Scler. 2012;18:1144–51.
79.Montalban, X, Hauser, SL, Kappos, L, et al.Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376:209–220.
80.Hawker, K, O’Connor, P, Freedman, MS, et al.Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66:460–471.
81.Fox, EJ, Markowitz, C, Applebee, A, et al.Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: findings from the phase III randomized ORATORIO trial. Mult Scler. 2018;24:1862–1870.
82.Sormani, MP, Li, DK, Bruzzi, P, et al.Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis. Neurology. 2011;77:1684–1690.
83.Sormani, MP, Gasperini, C, Romeo, M, et al.Assessing response to interferon-β in a multicenter dataset of patients with MS. Neurology. 2016;87:134–140.
84.Sormani, MP, Truffinet, P, Thangavelu, K, Rufi, P, Simonson, C, De Stefano, N.Predicting long-term disability outcomes in patients with MS treated with teriﬂunomide in TEMSO. Neurol Neuroimmunol Neuroinﬂamm. 2017;4:e379.
85.Boster, A, Hawker, K, Ritter, S, et al.Disease activity in the ﬁrst year predicts longer-term clinical outcomes in the pooled population of the phase III FREEDOMS and FREEDOMS II studies (P7.239). Neurology. 2015;84(14 suppl):P7.239.
86.Havrdová, E, Galetta, S, Hutchinson, M, et al.Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8:254–260.
87.Gärtner, J, Chitnis, T, Ghezzi, A, et al.Relapse rate and MRI activity in young adult patients with multiple sclerosis: a post hoc analysis of phase 3 fingolimod trials. Mult Scler J Exp Transl Clin. 2018;4:2055217318778610.
88.Giovannoni, G, Cook, S, Rammohan, K, et al.Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol. 2011;10:329–337.
89.Havrdová, E, Arnold, DL, Bar-Or, A, et al.No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. Mult Scler J Exp Transl Clin. 2018;4:2055217318760642.
90.Coles, AJ, Twyman, CL, Arnold, DL, et al.Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380:1829–1839.
91.Rotstein, DL, Healy, BC, Malik, MT, Chitnis, T, Weiner, HL.Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2015;72:152–158.
92.Hegen, H, Bsteh, G, Berger, T.‘No evidence of disease activity’ - is it an appropriate surrogate in multiple sclerosis? Eur J Neurol. 2018;25:1107–e101.
93.Goodin, DS, Reder, AT, Traboulsee, AL, et al.Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b. Mult Scler. 2019;25:837–847.
94.University of California, San Francisco MS-EPIC Team, Cree, BA, Gourraud, PA, et al.Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016;80:499–510.
95.Río, J, Rovira, À, Tintoré, M, et al.Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients. Mult Scler. 2018;24:322–330.
96.Prosperini, L, Mancinelli, CR, Haggiag, S, et al.Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2020;epublished January 23, 2020.
97.Scalfari, A, Neuhaus, A, Degenhardt, A, et al.The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain. 2010;133(Pt 7):1914–1929.
98.Bermel, RA, You, X, Foulds, P, et al.Predictors of long-term outcome in multiple sclerosis patients treated with interferon β. Ann Neurol. 2013;73:95–103.
99.Jokubaitis, VG, Spelman, T, Kalincik, T, et al.Predictors of long-term disability accrual in relapse-onset multiple sclerosis. Ann Neurol. 2016;80:89–100.
100.Mowry, EM, Pesic, M, Grimes, B, Deen, S, Bacchetti, P, Waubant, E.Demyelinating events in early multiple sclerosis have inherent severity and recovery. Neurology. 2009;72:602–608.
101.Naldi, P, Collimedaglia, L, Vecchio, D, et al.Predictors of attack severity and duration in multiple sclerosis: a prospective study. Open Neurol J. 2011;5:75–82.
102.Stewart, T, Spelman, T, Havrdova, E, et al.Contribution of different relapse phenotypes to disability in multiple sclerosis. Mult Scler. 2017;23:266–276.
103.Kurtzke, JF.Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–1452.
104.Kalincik, T, Cutter, G, Spelman, T, et al.Defining reliable disability outcomes in multiple sclerosis. Brain. 2015;138(Pt 11):3287–3298.
105.Kaufman, M, Moyer, D, Norton, J.The significant change for the Timed 25-foot Walk in the multiple sclerosis functional composite. Mult Scler. 2000;6:286–290.
106.Schwid, SR, Goodman, AD, McDermott, MP, Bever, CF, Cook, SD.Quantitative functional measures in MS: what is a reliable change? Neurology. 2002;58:1294–1296.
107.Feys, P, Lamers, I, Francis, G, et al.The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis. Mult Scler. 2017;23:711–720.
108.Hohol, MJ, Orav, EJ, Weiner, HL.Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology. 1995;45:251–255.
109.Learmonth, YC, Motl, RW, Sandroff, BM, Pula, JH, Cadavid, D.Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurol. 2013;13:37.
110.Norris, M, Anderson, R, Motl, RW, Hayes, S, Coote, S.Minimum number of days required for a reliable estimate of daily step count and energy expenditure, in people with MS who walk unaided. Gait Posture. 2017;53:201–206.
111.Motl, RW, Pilutti, LA, Learmonth, YC, Goldman, MD, Brown, T.Clinical importance of steps taken per day among persons with multiple sclerosis. PLoS One. 2013;8:e73247.
112.Lorscheider, J, Benkert, P, Schädelin, S, et al. Disability progression unrelated to relapses in relapsing-remitting multiple sclerosis: insights from the Swiss multiple sclerosis cohort study (abstract 273). Presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Stockholm, Sweden, October 11-13, 2019.
113.Traboulsee, A, Simon, JH, Stone, L, et al.Revised recommendations of the Consortium of MS Centers Task Force for a standardized MRI protocol and clinical guidelines for the diagnosis and follow-up of multiple sclerosis. AJNR Am J Neuroradiol. 2016;37:394–401.
114.Miller, DH, Rudge, P, Johnson, G, et al.Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain. 1988;111(pt 4):927–939.
115.Bellanger, G, Biotti, D, Patsoura, S, et al.What is the relevance of the systematic use of gadolinium during the MRI follow-up of multiple sclerosis patients under natalizumab? Clin Neuroradiol. 2019;epublished May 29, 2019.
116.Tsantes, E, Curti, E, Puci, F, et al. The contribution of enhancing lesions in monitoring multiple sclerosis treatment: is gadolinium always necessary? Abstract EPO3207. Presented at the European Academy of Neurology annual meeting, June 29-July 2, 2019.
117.Zivadinov, R, Bergsland, N, Hagemeier, J, et al.Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS. Neurology. 2019;93:e611–e623.
118.Zecca, C, Disanto, G, Sormani, MP, et al.Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis. Mult Scler. 2016;22:782–791.
119.Granella, F, Tsantes, E, Graziuso, S, Bazzurri, V, Crisi, G, Curti, E.Spinal cord lesions are frequently asymptomatic in relapsing-remitting multiple sclerosis: a retrospective MRI survey. J Neurol. 2019;266:3031–3037.
120.Casserly, C, Seyman, EE, Alcaide-Leon, P, et al.Spinal cord atrophy in multiple sclerosis: a systematic review and meta-analysis. J Neuroimaging. 2018;28:556–586.
121.Opfer, R, Ostwaldt, AC, Sormani, MP, et al.Estimates of age-dependent cutoffs for pathological brain volume loss using SIENA/FSL-a longitudinal brain volumetry study in healthy adults. Neurobiol Aging. 2018;65:1–6.
122.Opfer, R, Ostwaldt, AC, Walker-Egger, C, et al.Within-patient fluctuation of brain volume estimates from short-term repeated MRI measurements using SIENA/FSL. J Neurol. 2018;265:1158–1165.
123.Galassi, S, Prosperini, L, Logoteta, A, et al.A lesion topography-based approach to predict the outcomes of patients with multiple sclerosis treated with interferon beta. Mult Scler Relat Disord. 2016;8:99–106.
124.Chard, DT, Brex, PA, Ciccarelli, O, et al.The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14 year follow up study. J Neurol Neurosurg Psychiatry. 2003;74:1551–1554.
125.Sombekke, MH, Wattjes, MP, Balk, LJ, et al.Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis. Neurology. 2013;80:69–75.
126.Brownlee, WJ, Altmann, DR, Prados, F, et al.Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis. Brain. 2019;142:2276–2287.
127.Planche, V, Gibelin, M, Cregut, D, Pereira, B, Clavelou, P.Cognitive impairment in a population-based study of patients with multiple sclerosis: differences between late relapsing-remitting, secondary progressive and primary progressive multiple sclerosis. Eur J Neurol. 2016;23:282–289.
128.Rao, SM, Leo, GJ, Ellington, L, Nauertz, T, Bernardin, L, Unverzagt, F.Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology. 1991;41:692–696.
129.Ruet, A, Deloire, M, Hamel, D, Ouallet, JC, Petry, K, Brochet, B.Cognitive impairment, health-related quality of life and vocational status at early stages of multiple sclerosis: a 7-year longitudinal study. J Neurol. 2013;260:776–784.
130.Morrow, SA, Classen, S, Monahan, M, et al.On-road assessment of fitness-to-drive in persons with MS with cognitive impairment: a prospective study. Mult Scler. 2018;24:1499–1506.
131.Kalb, R, Beier, M, Benedict, RHB, et al.Recommendations for cognitive screening and management in multiple sclerosis care. Mult Scler. 2018;24:1665–1680.
132.Benedict, RHB, DeLuca, J, Phillips, G, et al.Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis. Mult Scler. 2017;23:721–733.
133.Walker, LAS, Marino, D, Berard, JA, Feinstein, A, Morrow, SA, Cousineau, D.Canadian normative data for minimal assessment of cognitive function in multiple sclerosis. Can J Neurol Sci. 2017;44:547–555.
134.Morrow, SA, O’Connor, PW, Polman, CH, et al.Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks. Mult Scler. 2010;16:1385–1392.
135.Benedict, RH, Morrow, S, Rodgers, J, et al.Characterizing cognitive function during relapse in multiple sclerosis. Mult Scler. 2014;20:1745–1752.
136.Riepl, E, Pfeuffer, S, Ruck, T, et al.Alemtuzumab improves cognitive processing speed in active multiple sclerosis-a longitudinal observational study. Front Neurol. 2018;8:730.
137.Gudesblatt, M, Wissemann, K, Zarif, M, et al.Improvement in cognitive function as measured by NeuroTrax in patients with relapsing multiple sclerosis treated with natalizumab: a 2-year retrospective analysis. CNS Drugs. 2018;32:1173–1181.
138.Benedict, RH, de Seze, J, Hauser, SL, et al. Impact of ocrelizumab on cognition in patients at increased risk of developing progressive disease (abstract DX67) Presented at the Consortium of Multiple Sclerosis Centers annual meeting, Nashville TN, May 30-June 2, 2018.
139.Zipoli, V, Tortorella, P, Goretti, B, et al. Effect of delayed-release dimethyl fumarate on cognition in Italian patients with relapsing remitting multiple sclerosis: the phase 4 StarTec study (abstract P457). Presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Germany, October 10–12, 2018.
140.Cree, BA, Goldman, MD, Corboy, JR, et al. Effect of fingolimod on functional disability, cognition and quality of life outcomes versus glatiramer acetate in relapsing-remitting multiple sclerosis patients: results from the ASSESS study (abstract EPO1230). Presented at the 5th Congress of the European Academy of Neurology, Oslo, Norway, June 29-July 2, 2019.
141.Sprenger, T, Kappos, L, Radue, EW, et al.Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide. Mult Scler. 2019;epublished June 14, 2019.
142.Chalmer, TA, Kalincik, T, Laursen, B, Sorensen, PS, Magyari, M, Members of Danish Multiple Sclerosis Group. Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy. J Neurol. 2019;266:306–315.
143.Zhovtis Ryerson, L, Frohman, TC, Foley, J, et al.Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016;87:885–889.
144.Scarpazza, C, De Rossi, N, Tabiadon, G, Turrini, MV, Gerevini, S, Capra, R.Four cases of natalizumab-related PML: a less severe course in extended interval dosing? Neurol Sci. 2019;40:2119–2124.
145.Prosperini, L, Kinkel, RP, Miravalle, AA, Iaffaldano, P, Fantaccini, S.Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis. Ther Adv Neurol Disord. 2019;12:1756286419837809.
146.Vollmer, B, Honce, JM, Sillau, S, et al.The impact of very short transition times on switching from natalizumab to fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosis. J Neurol Sci. 2018;390:89–93.
147.Pfeuffer, S, Schmidt, R, Straeten, FA, et al.Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation. J Neurol. 2019;266:165–173.
148.Fragoso, YD, Adoni, T, Gomes, S, et al.Severe exacerbation of multiple sclerosis following withdrawal of fingolimod. Clin Drug Investig. 2019;39:909–913.
149.Vermersch, P, Radue, EW, Putzki, N, Ritter, S, Merschhemke, M, Freedman, MS.A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin. 2017;3:2055217317730096.
150.Schmidt, S, Schulten, T.Severe rebound after cessation of fingolimod treated with ocrelizumab with coincidental transient aggravation: report of two cases. Ther Adv Neurol Disord. 2019;12:1756286419846818.
151.Holmøy, T, Torkildsen, Ø, Zarnovicky, S.Extensive multiple sclerosis reactivation after switching from fingolimod to rituximab. Case Rep Neurol Med. 2018;2018:5190794.
152.Bernard-Valnet, R, Pignolet, B, Biotti, D, et al.Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab. Mult Scler Relat Disord. 2018;25:216–218.
153.Huhn, K, Bayas, A, Doerck, S, et al.Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study. J Neurol. 2018;265:1521–1527.
154.Alcalá, C, Gascón, F, Pérez-Miralles, F, Domínguez, JA, Gil-Perotín, S, Casanova, B.Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. J Neurol. 2019;266:726–734.
155.Cabrera-Maqueda, JM, Fuentes-Rumí, L, Carreón-Guarnizo, E, et al. Lymphocyte subsets recovery time following first alemtuzumab course in multiple sclerosis patients previously treated with fingolimod (abstract P935). Presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Germany, October 10–12, 2018.
156.Mavenclad (cladribine) Product Monograph. EMD Serono, November 29, 2017.
157.Cook, S, Leist, T, Comi, G, et al.Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis. Mult Scler Relat Disord. 2019;29:157–167.
158.Giovannoni, G, Soelberg Sorensen, P, Cook, S, et al.Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler. 2018;24:1594–1604.
159.Mayer, L, Kappos, L, Racke, MK, et al.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult Scler Relat Disord. 2019;30:236–243.
161.Ciardi, MR, Iannetta, M, Zingaropoli, MA, et al.Reactivation of hepatitis B virus with immune-escape mutations after ocrelizumab treatment for multiple sclerosis. Open Forum Infect Dis. 2018;6:ofy356.
162.Giovannoni, G, Kappos, L, Hauser, SL, et al. Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis (abstract P1015). Presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Stockholm, Sweden, September 11-13, 2019.
163.Derfuss, T, Weber, MS, Hughes, R, et al. Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions (abstract 65). Presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Stockholm, Sweden, September 11–13, 2019.
164.Makatsori, M, Kiani-Alikhan, S, Manson, AL, et al.Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes. QJM. 2014;107:821–828.
165.Baker, D, Herrod, SS, Alvarez-Gonzalez, C, Giovannoni, G, Schmierer, K.Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab. JAMA Neurol. 2017;74:961–969.
166.Buonomo, AR, Zappulo, E, Viceconte, G, Scotto, R, Borgia, G, Gentile, I.Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis. Expert Opin Drug Saf. 2018;17:709–717.
167.Lemtrada (alemtuzumab) Product Monograph. Sanofi Genzyme, January 16, 2019.
168.Montalban, X, Arnold, DL, Boyko, AN, et al. Alemtuzumab maintains efficacy on clinical and MRI disease activity outcomes, including slowing of brain volume loss, over 9 years in RRMS patients: CARE-MS I follow-up (TOPAZ study) (abstract P974). Presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Stockholm, Sweden, September 11–13, 2019.
169.Schippling, S, Bass, AD, Boster, A, et al. Additional courses of alemtuzumab improved clinical and MRI outcomes in pooled CARE-MS I and II patients with disease activity after three courses: analysis of patients who received ≥4 courses (abstract P628). Presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Germany, October 10–12, 2018.
170.Hyun, JW, Kim, Y, Kim, G, Kim, SH, Kim, HJ.Severe B cell-mediated disease activation despite two cycles of alemtuzumab in a patient with multiple sclerosis. Mult Scler. 2019;25:1942–1945.
171.Wehrum, T, Beume, LA, Stich, O, et al.Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis. Neurology. 2018;90:e601–e605.
172.Massey, J, Barnett, Y, Curnow, J, Sutton, I.B cell depletion therapy resulting in sustained remission of severe autoimmune complications following alemtuzumab treatment of multiple sclerosis. Mult Scler Relat Disord. 2019;35:100–103.
173.Muraro, PA, Pasquini, M, Atkins, HL, et al.Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. JAMA Neurol. 2017;74:459–469.
174.Burt, RK, Balabanov, R, Burman, J, et al.Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. JAMA. 2019;321:165–174.
175.Rush, CA, MacLean, HJ, Freedman, MS.Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nat Rev Neurol. 2015;11:379–389.
176.Fox, RJ, Cree, BAC, De Sèze, J, et al.MS disease activity in RESTORE – a randomized 24-week natalizumab treatment interruption study. Neurology. 2014;82:1491–1498.
177.Havla, J, Gerdes, LA, Meinl, I, et al.De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. J Neurol. 2011;258:1665–1669.
178.Cohan, SL, Edwards, K, Lucas, L, et al.Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy. Mult Scler J Exp Transl Clin. 2019;5:2055217318824618.
179.Cohan, SL, Moses, H, Calkwood, J, et al.Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: a multicenter retrospective observational study (STRATEGY). Mult Scler Relat Disord. 2018;22:27–34.
180.Salavisa, M, Serrazina, F, Ladeira, F, Correia, AS. Discontinuation of disease-modifying therapy and its clinical impact in MS patients over 60 years (abstract P703). Presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Stockholm, Sweden, September 11–13, 2019.
181.Birnbaum, G.Stopping disease-modifying therapy in nonrelapsing multiple sclerosis: experience from a clinical practice. Int J MS Care. 2017;19:11–14.
182.Schweitzer, F, Laurent, S, Fink, GR, et al.Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis. Curr Opin Neurol. 2019;32:305–312.
183.Kalincik, T, Malpas, C, Sharmin, S, et al. Modifiers of the effectiveness of MS immunotherapies (abstract P1421). Presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Stockholm, Sweden, October 11–13, 2019.
184.Bastian, I, Coulter, C.National Tuberculosis Advisory Committee (NTAC). Position statement on interferon-γ release assays for the detection of latent tuberculosis infection. Commun Dis Intell Q Rep. 2017;41:E322–E336.
185.Kwon, YS, Kim, YH, Jeon, K, et al.Factors that predict negative results of QuantiFERON-TB Gold In-Tube test in patients with culture-confirmed tuberculosis: a multicenter retrospective cohort study. PLoS One. 2015;10:e0129792.
186.Baber, U, Bouley, A, Egnor, E, Sloane, JA.Anti-JC virus antibody index changes in rituximab-treated multiple sclerosis patients. J Neurol. 2018;265:2342–2345.
187.Kadish, R, Robertson, D, Sweeney, M.Fatal leukoencephalopathy in a patient with multiple sclerosis following treatment with ocrelizumab. Neurology. 2018;90(15 Supplement): P5.353.
188.Sinnecker, T, Othman, J, Kühl, M, et al.Progressive multifocal leukoencephalopathy in a multiple sclerosis patient diagnosed after switching from natalizumab to fingolimod. Case Rep Neurol Med. 2016;2016:5876798.
189.Grebenciucova, E, Berger, JR.Immunosenescence: the role of aging in the predisposition to neuro-infectious complications arising from the treatment of multiple sclerosis. Curr Neurol Neurosci Rep. 2017;17:61.
190.Kapoor, R, Ho, PR, Campbell, N, et al.Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol. 2018;17:405–415.
191.Paolillo, A, Coles, AJ, Molyneux, PD, et al.Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology. 1999;53:751–757.
192.Lublin, F, Miller, DH, Freedman, MS, et al.Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387:1075–1084.
193.Luchetti, S, Fransen, NL, van Eden, CG, Ramaglia, V, Mason, M, Huitinga, I.Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis. Acta Neuropathol. 2018;135:511–528.
194.Frischer, JM, Weigand, SD, Guo, Y, et al.Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol. 2015;78:710–721.
195.Mayzent (siponimod) U.S. Product Monograph. Novartis Pharmaceuticals Corp., March 26, 2019.
196.Kappos, L, Bar-Or, A, Cree, BAC, et al.Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391:1263–1273.
197.Mavenclad (cladribine) U.S. Product Monograph. EMD Serono, March 29, 2019.
198.Rice, GP, Filippi, M, Comi, G.Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology. 2000;54:1145–1155.
199.Beutler, E, Sipe, JC, Romine, JS, Koziol, JA, McMillan, R, Zyroff, J.The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci USA. 1996;93:1716–1720.
200.Kister, I, Spelman, T, Alroughani, R, et al.Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. J Neurol Neurosurg Psychiatry. 2016;87:1133–1137.
201.Cohen, JA, Cutter, GR, Fischer, JS, et al.Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology. 2002;59:679–687.
202.Panitch, H, Miller, A, Paty, D, Weinshenker, B, North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology. 2004;63:1788–1795.
203.Knox, KB, Saini, A, Levin, MC.The dilemma of when to stop disease-modifying therapy in multiple sclerosis: a narrative review and Canadian regional reimbursement policies. Int J MS Care. 2019. Published online: 22 May 2019. doi:10.7224/1537-2073.2018-107
204.Ayrignac, X, Bilodeau, PA, Prat, A, et al.Assessing the risk of multiple sclerosis disease-modifying therapies. Expert Rev Neurother. 2019;19:695–706.
205.Hughes, SE, Spelman, T, Gray, OM, et al.Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Mult Scler. 2014;20:739–746.
206.Portaccio, E, Tudisco, L, Pastò, L, et al. Pregnancy in women with active multiple sclerosis increases the risk of disability progression (abstract P409). Presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Stockholm, Sweden, October 11–13, 2019.
207.Coyle, PK, Oh, J, Magyari, M, Oreja-Guevara, C, Houtchens, M.Management strategies for female patients of reproductive potential with multiple sclerosis: an evidence-based review. Mult Scler Relat Disord. 2019;32:54–63.
208.Gilenya (fingolimod) Product Monograph. Novartis Pharmaceuticals Canada, May 2, 2019.
209.Portaccio, E, Annovazzi, P, Ghezzi, A, et al.Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. Neurology. 2018;90:e823–e831.
210.Haghikia, A, Langer-Gould, A, Rellensmann, G, et al.Natalizumab use during the third trimester of pregnancy. JAMA Neurol. 2014;71:891–895.
211.Hellwig, K, Haghikia, A, Rockhoff, M, Gold, R.Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Ther Adv Neurol Disord. 2012;5:247–253.
212.Avila-Ornelas, J, Avila, M, Stosic, M, et al.The role of postpartum intravenous corticosteroids in the prevention of relapses in multiple sclerosis. Int J MS Care. 2011;13:91–93.
213.Winkelmann, A, Rommer, PS, Hecker, M, Zettl, UK.Intravenous immunoglobulin treatment in multiple sclerosis: a prospective, rater-blinded analysis of relapse rates during pregnancy and the postnatal period. CNS Neurosci Ther. 2019;25:78–85.
214.Almas, S, Vance, J, Baker, T, Hale, T.Management of multiple sclerosis in the breastfeeding mother. Mult Scler Int. 2016;2016:6527458.
215.Polman, CH, Reingold, SC, Banwell, B, et al.Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292–302.
216.Hennes, EM, Baumann, M, Lechner, C, Rostásy, K.MOG spectrum disorders and role of MOG-antibodies in clinical practice. Neuropediatrics. 2018;49:3–11.
217.Krysko, KM, Graves, J, Rensel, M, et al.Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US. Neurology. 2018;91:e1778–e1787.
218.Chitnis, T, Arnold, DL, Banwell, B, et alTrial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis. N Engl J Med. 2018;379:1017–1027.
219.Chitnis, T, Ghezzi, A, Bajer-Kornek, B, Boyko, A, Giovannoni, G, Pohl, D.Pediatric multiple sclerosis: escalation and emerging treatments. Neurology. 2016;87(9 Suppl 2):S103–S109.
220.Huppke, B, Ellenberger, D, Hummel, H, et al.Association of obesity with multiple sclerosis risk and response to first-line disease modifying drugs in children. JAMA Neurol. 2019;epublished July 15, 2019.
221.McKay, KA, Manouchehrinia, A, Berrigan, L, Fisk, JD, Olsson, T, Hillert, J.Long-term cognitive outcomes in patients with pediatric-onset vs adult-onset multiple sclerosis. JAMA Neurol. 2019;epublished June 17, 2019.